Clinical Trial

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and preliminarily evaluating a machine learning model to discriminate ATTR-CM cases from HF controls without ATTR-CM.
Trial Details
NCT Number NCT07690436
Lead Sponsor AstraZeneca
Conditions Transthyretin Amyloid Cardiomyopathy
Enrollment 500 participants
Start Date 2026-07-02
Primary Completion 2027-06-03 (estimated)
Study Completion 2027-06-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-08